SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients ...
Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback